NCT04510649View on ClinicalTrials.gov

Surufatinib DDI With a PPI and a CYP3A Inducer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

September 11, 2020

Study Completion Date

March 2, 2021

Conditions
Healthy
Interventions
DRUG

Part A

in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11

DRUG

Part B

in Part B, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 12 and receive Rifampin 600 mg single dose on study days 5 through 16

Trial Locations (1)

90630

West Coast Clinical Trials (WCCT), Cypress

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT04510649 - Surufatinib DDI With a PPI and a CYP3A Inducer | Biotech Hunter | Biotech Hunter